Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9466MR)

This product GTTS-WQ9466MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9466MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3813MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ183MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ14341MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ5678MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ10564MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ11274MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ2925MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ12471MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW